Altimmune meets NASH goal in phase I
![Photo: Colourbox](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14407160.ece/ALTERNATES/schema-16_9/doc7mr9y9ozf4x1f5u2l5bq.jpg)
Biotech company Altimmune has reached its primary and secondary endpoints in a phase Ib study of its obesity and non-alcoholic steatohepatitis (NASH) treatment, industry media Fierce Biotech reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer drops phase II-ready NASH candidate
For subscribers